puma 4d

Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. 8979 4d Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. cambodia 4d result Antibody-drug conjugates are a novel and promising treatment class in this setting Datopotamab deruxtecan (Dato-DXd) consists of a